<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807868</url>
  </required_header>
  <id_info>
    <org_study_id>1628655</org_study_id>
    <nct_id>NCT04807868</nct_id>
  </id_info>
  <brief_title>AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)</brief_title>
  <acronym>AVAIL</acronym>
  <official_title>AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berg, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to create a resource that will advance research that is focused&#xD;
      on discovery of novel therapies, risk stratification, and aggressive interventions for those&#xD;
      at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will&#xD;
      generate a biobank of liver tissue collected during standard of care liver biopsies. Paired&#xD;
      blood/urine samples, FibroScan and relevant data will also be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Creation of a Biobank of Liver Tissue Paired with a Registry of Histological and Clinical Metadata</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creation of a Biobank of Blood and Urine Samples Paired with a Registry of Associated Histological and Clinical Metadata</measure>
    <time_frame>Baseline with annual follow up for up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver Fat and Fibrosis Over Time ad Measured with FibroScan Controlled Attenuation Parameter and Vibration Controlled Transient Elastography, respectively</measure>
    <time_frame>Baseline with annual follow up for up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Biopsy Group</arm_group_label>
    <description>Adults undergoing a standard of care liver biopsy at AdventHealth Central Florida Division for any reason</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Biopsy Group</arm_group_label>
    <description>Adults without any history of NAFLD</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care liver biopsy</intervention_name>
    <description>Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.</description>
    <arm_group_label>Biopsy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fibroscan</intervention_name>
    <description>A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.</description>
    <arm_group_label>Biopsy Group</arm_group_label>
    <arm_group_label>Non-Biopsy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Blood and urine will be collected.</description>
    <arm_group_label>Biopsy Group</arm_group_label>
    <arm_group_label>Non-Biopsy Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver tissue, fasting blood and spot urine will be collected&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with Non-alcoholic fatty liver disease (NAFLD) and adults without any history of&#xD;
        NAFLD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Females and Males ≥ 18 years of age.&#xD;
&#xD;
          -  Understands the procedures and agrees to participate by giving written informed&#xD;
             consent.&#xD;
&#xD;
        Biopsy Group Only:&#xD;
&#xD;
        • Scheduled for standard of care liver biopsy for any reason.&#xD;
&#xD;
        Non-Biopsy Group Only:&#xD;
&#xD;
        • BMI ≥ 25, with or without type 2 diabetes, without any level of NAFLD based on: (1)&#xD;
        Recent medical history (within 6 months of screening visit). (2) Data collected from&#xD;
        participation in a prior research study where they consented to be re-contacted for future&#xD;
        studies.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Women who are pregnant when referred for a liver biopsy will be excluded.&#xD;
&#xD;
          -  Presence of any condition that, in the opinion of the Investigator, compromises&#xD;
             participant safety or data integrity or the participant's ability to complete the&#xD;
             study.&#xD;
&#xD;
        Otherwise, all eligible patients who consent will be included in AVAIL. If participants in&#xD;
        the non-biopsy group are found to have NAFLD based on the FibroScan done for this study,&#xD;
        then they will be informed of this and advised to follow up with their physician. Their&#xD;
        data will still be part of the registry and analyzed with the biopsy group that is found to&#xD;
        have NAFLD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Corbin, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>Fh.tri.recruitment@adventhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.adventhealthresearchinstitute.com/research/translational-research</url>
    <description>Website for AdventHealth Translational Research Institute</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

